The latest price target for Mereo BioPharma Group (NASDAQ:MREO) was reported by BTIG on May 12, 2026. The analyst firm set a price target for $1.00 expecting MREO to rise to within 12 months (a possible 306.17% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Mereo BioPharma Group (NASDAQ:MREO) was provided by BTIG, and Mereo BioPharma Group reiterated their buy rating.

There is no last upgrade for Mereo BioPharma Group

The last downgrade for Mereo BioPharma Group PLC happened on March 23, 2026 when JP Morgan changed their price target from N/A to N/A for Mereo BioPharma Group PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mereo BioPharma Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mereo BioPharma Group was filed on May 12, 2026 so you should expect the next rating to be made available sometime around May 12, 2027.

While ratings are subjective and will change, the latest Mereo BioPharma Group (MREO) rating was a reiterated with a price target of $1.00 to $1.00. The current price Mereo BioPharma Group (MREO) is trading at is $0.25, which is out of the analyst’s predicted range.